Prasugrel to lead Japan-origin blockbusters
This article was originally published in Scrip
Executive Summary
Now with a key US approval recommendation under its belt, Daiichi Sankyoand Lilly's novel antiplatelet agent prasugrel (Effient) is set to reap peak global annual sales of $2.5 billion. Sales in Japan, where the product is still in Phase II development, could reach ¥40 billion ($438.6 million) a year, a new Japanese analysis predicts.